Biocept to Collaborate on Biopharma Company Clinical Trial by Identifying Biomarkers Found in Cerebral Spinal Fluid for Patients with Lung Cancer that has Spread to the Brain
"Our technology has the high sensitivity required to detect biomarkers using both CTCs and ctDNA in fluids beyond blood, including CSF," said
Brain metastases and leptomeningeal disease are prevalent in patients with solid tumors, including those with NSCLC. Radiation therapy has been used to control the symptoms of these patients, due to the inability of the majority of available therapeutic drugs to penetrate the blood-brain barrier, the body's natural defense system. However, new therapeutic molecules in development are demonstrating the ability to penetrate the blood-brain barrier more effectively, thus providing the potential for new therapeutic options.
"Finding effective treatments for patients with brain metastases and leptomeningeal disease is a critical unmet medical need because of the inability of most drugs to cross the blood-brain barrier," said
About
Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this release are not strictly historical, including without limitation statements as to our ability to improve the detection
and treatment of cancer, our ability to analyze biomarkers in fluids beyond blood (including CSF), new therapeutic molecules having the ability to penetrate the blood-brain barrier, our ability to obtain data that provides clinical validation of our liquid biopsy tests to detect and monitor important biomarkers in CSF, our impact on diagnostic strategies, our ability to enhance individual cancer treatments and our plans to introduce CLIA-validated assays for prostate cancer and other solid tumors in the near term, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our
Logo - http://photos.prnewswire.com/prnh/20151013/276540LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/biocept-to-collaborate-on-biopharma-company-clinical-trial-by-identifying-biomarkers-found-in-cerebral-spinal-fluid-for-patients-with-lung-cancer-that-has-spread-to-the-brain-300238586.html
SOURCE
News Provided by Acquire Media